These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

416 related items for PubMed ID: 21964009

  • 1. Under-use of secondary prevention medication in acute coronary syndrome patients treated with in-hospital coronary artery bypass graft surgery.
    Looi KL, Chow KL, Looi JL, Lee M, Halliday S, White H, Ellis C.
    N Z Med J; 2011 Sep 23; 124(1343):18-27. PubMed ID: 21964009
    [Abstract] [Full Text] [Related]

  • 2. [Evaluation of hospitalization period and five-year follow-up of patients admitted with acute coronary syndrome following coronary artery bypass graft surgery].
    Can LH, Kayıkçıoğlu M, Yavuzgil O, Kültürsay H, Soydan I.
    Turk Kardiyol Dern Ars; 2010 Sep 23; 38(6):387-92. PubMed ID: 21200116
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Outcomes associated with the use of secondary prevention medications after coronary artery bypass graft surgery.
    Goyal A, Alexander JH, Hafley GE, Graham SH, Mehta RH, Mack MJ, Wolf RK, Cohn LH, Kouchoukos NT, Harrington RA, Gennevois D, Gibson CM, Califf RM, Ferguson TB, Peterson ED, PREVENT IV Investigators.
    Ann Thorac Surg; 2007 Mar 23; 83(3):993-1001. PubMed ID: 17307447
    [Abstract] [Full Text] [Related]

  • 6. Should all patients be treated with an angiotensin-converting enzyme inhibitor after coronary artery bypass graft surgery? The impact of angiotensin-converting enzyme inhibitors, statins, and β-blockers after coronary artery bypass graft surgery.
    Kalavrouziotis D, Buth KJ, Cox JL, Baskett RJ.
    Am Heart J; 2011 Nov 23; 162(5):836-43. PubMed ID: 22093199
    [Abstract] [Full Text] [Related]

  • 7. Use of evidence-based management for acute coronary syndrome.
    Tang E, Wong CK, Wilkins G, Herbison P, Williams M, Kay P, Restieaux N.
    N Z Med J; 2005 Oct 07; 118(1223):U1678. PubMed ID: 16224502
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Use of perioperative cardiac medical therapy among patients undergoing coronary artery bypass graft surgery.
    Filion KB, Pilote L, Rahme E, Eisenberg MJ.
    J Card Surg; 2008 Oct 07; 23(3):209-15. PubMed ID: 18435634
    [Abstract] [Full Text] [Related]

  • 10. The impact of pharmacist-initiated interventions in improving acute coronary syndrome secondary prevention pharmacotherapy prescribing upon discharge.
    Hassan Y, Kassab Y, Abd Aziz N, Akram H, Ismail O.
    J Clin Pharm Ther; 2013 Apr 07; 38(2):97-100. PubMed ID: 23441979
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Secondary prevention following coronary artery bypass grafting has improved but remains sub-optimal: the need for targeted follow-up.
    Turley AJ, Roberts AP, Morley R, Thornley AR, Owens WA, de Belder MA.
    Interact Cardiovasc Thorac Surg; 2008 Apr 07; 7(2):231-4. PubMed ID: 18234766
    [Abstract] [Full Text] [Related]

  • 13. Invasive vs non-invasive treatment in acute coronary syndromes and prior bypass surgery.
    Gurfinkel EP, Perez de la Hoz R, Brito VM, Duronto E, Dabbous OH, Gore JM, Anderson FA, GRACE Investigators.
    Int J Cardiol; 2007 Jun 25; 119(1):65-72. PubMed ID: 17045681
    [Abstract] [Full Text] [Related]

  • 14. Self-reported use of evidence-based medicine and smoking cessation 6 - 9 months after acute coronary syndrome: a single-centre perspective.
    Griffiths B, Lesosky M, Ntsekhe M.
    S Afr Med J; 2014 Jun 17; 104(7):483-7. PubMed ID: 25214049
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Evaluation of preventive cardiovascular pharmacotherapy after coronary artery bypass graft surgery.
    Barry AR, Koshman SL, Norris CM, Ross DB, Pearson GJ.
    Pharmacotherapy; 2014 May 17; 34(5):464-72. PubMed ID: 24877186
    [Abstract] [Full Text] [Related]

  • 17. API expert consensus document on management of ischemic heart disease.
    Association of Physicians of India.
    J Assoc Physicians India; 2006 Jun 17; 54():469-80. PubMed ID: 16909697
    [Abstract] [Full Text] [Related]

  • 18. Treatment and secondary prevention of ischemic coronary events in Croatia (TASPIC-CRO study).
    Reiner Z, Mihatov S, Milicić D, Bergovec M, Planinc D, TASPIC-CRO Study Group Investigators.
    Eur J Cardiovasc Prev Rehabil; 2006 Aug 17; 13(4):646-54. PubMed ID: 16874158
    [Abstract] [Full Text] [Related]

  • 19. Patients undergoing coronary revascularisation: a missed opportunity for secondary prevention?
    Fox DJ, Kibiro M, Eichhöfer J, Curzen NP.
    Postgrad Med J; 2005 Jun 17; 81(956):401-3. PubMed ID: 15937208
    [Abstract] [Full Text] [Related]

  • 20. Use and cost of branded and generic drugs in patients with coronary heart disease--results from a prospective survey of 1008 patients in two London hospitals.
    Corp EV, Antoniou S, Wright PG, Khachi H, Vercaeren S, Wald DS.
    QJM; 2009 Dec 17; 102(12):843-9. PubMed ID: 19828644
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.